BioCentury | Sep 13, 2019
Distillery Therapeutics

Treating antibiotic-resistant Gram-negative infection with stapled antimicrobial peptides

...of stapled peptides derived from the antimicrobial peptide (AMP) magainin II. Computational design of stapled magainin...
...Aug. 19, 2019 doi:10.1038/s41587-019-0222-z CONTACT: Loren D. Walensky, Dana-Farber Cancer Institute, Boston, Mass. e-mail: loren_walensky@dfci.harvard.edu Sandi Wong Magainin Dana-Farber...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...First-generation attempts to develop these peptides as therapeutics, including the magainin class of molecules from Magainin...
...added that many of the topical antimicrobial peptides in the clinic are built on the magainin...
...Haifa Bay, Israel Tuskegee University, Tuskegee, Ala. U.S. Department of Defense, Washington, D.C. Erin McCallister, Senior Editor RP182 Magainin Riptide...
BioCentury | Mar 10, 2014
Company News

Ohr, Cold Spring Harbor Laboratory deal

...small molecule inhibitor of protein tyrosine phosphatase 1B ( PTP-1B ; PTPN1 ), from now-defunct Genaera Corp....
BioCentury | Apr 15, 2013
Company News

SunPharm board of directors update

...SUNP), Jacksonville, Fla. Business: Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Jay Moorin, president and CEO of Magainin...
BioCentury | Apr 15, 2013
Clinical News

Magainin preclinical data

...the data support MSI-1436 as a candidate for Phase I trials to treat HIV infection. Magainin...
BioCentury | Oct 31, 2011
Clinical News

MEDI-528: Development discontinued

...the milestone and royalty rights from now-defunct Genaera Corp. (see BioCentury, May 31, 2010). In 2001, Genaera...
BioCentury | Oct 28, 2011
Clinical News

AstraZeneca discontinues MEDI-528

...IL-9. Last year, Ligand acquired the milestone and royalty rights from now-defunct Genaera Corp. In 2001, Genaera...
BioCentury | Oct 6, 2011
Targets & Mechanisms

Shark versus virus

...research and translational science at the Georgetown University Medical Center , identified squalamine in 1993. Magainin...
...positioned it as an angiogenesis inhibitor for cancer. In 2001, Magainin changed its name to Genaera Corp....
...unlikely to improve vision with the speed or frequency necessary to compete with marketed treatments. Genaera...
BioCentury | Jul 25, 2011
Clinical News

Ohr preclinical data

...of ocular toxicity or changes in intraocular pressure. In 2009, Ohr acquired Evizon squalamine from Genaera Corp....
...to reformulate the compound to develop it for the indication (see BioCentury, Dec. 7, 2009). Genaera's...
BioCentury | Mar 7, 2011
Clinical News

MEDI-528: Completed Phase IIb enrollment

...subcutaneous MEDI-528. Last May, Ligand acquired the milestone and royalty rights to MEDI-528 from Genaera Corp. Genaera...
...to develop mAbs against IL-9 (see BioCentury, May 31, 2010). Genaera's assets were transferred to Genaera...
Items per page:
1 - 10 of 326
BioCentury | Sep 13, 2019
Distillery Therapeutics

Treating antibiotic-resistant Gram-negative infection with stapled antimicrobial peptides

...of stapled peptides derived from the antimicrobial peptide (AMP) magainin II. Computational design of stapled magainin...
...Aug. 19, 2019 doi:10.1038/s41587-019-0222-z CONTACT: Loren D. Walensky, Dana-Farber Cancer Institute, Boston, Mass. e-mail: loren_walensky@dfci.harvard.edu Sandi Wong Magainin Dana-Farber...
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...First-generation attempts to develop these peptides as therapeutics, including the magainin class of molecules from Magainin...
...added that many of the topical antimicrobial peptides in the clinic are built on the magainin...
...Haifa Bay, Israel Tuskegee University, Tuskegee, Ala. U.S. Department of Defense, Washington, D.C. Erin McCallister, Senior Editor RP182 Magainin Riptide...
BioCentury | Mar 10, 2014
Company News

Ohr, Cold Spring Harbor Laboratory deal

...small molecule inhibitor of protein tyrosine phosphatase 1B ( PTP-1B ; PTPN1 ), from now-defunct Genaera Corp....
BioCentury | Apr 15, 2013
Company News

SunPharm board of directors update

...SUNP), Jacksonville, Fla. Business: Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Jay Moorin, president and CEO of Magainin...
BioCentury | Apr 15, 2013
Clinical News

Magainin preclinical data

...the data support MSI-1436 as a candidate for Phase I trials to treat HIV infection. Magainin...
BioCentury | Oct 31, 2011
Clinical News

MEDI-528: Development discontinued

...the milestone and royalty rights from now-defunct Genaera Corp. (see BioCentury, May 31, 2010). In 2001, Genaera...
BioCentury | Oct 28, 2011
Clinical News

AstraZeneca discontinues MEDI-528

...IL-9. Last year, Ligand acquired the milestone and royalty rights from now-defunct Genaera Corp. In 2001, Genaera...
BioCentury | Oct 6, 2011
Targets & Mechanisms

Shark versus virus

...research and translational science at the Georgetown University Medical Center , identified squalamine in 1993. Magainin...
...positioned it as an angiogenesis inhibitor for cancer. In 2001, Magainin changed its name to Genaera Corp....
...unlikely to improve vision with the speed or frequency necessary to compete with marketed treatments. Genaera...
BioCentury | Jul 25, 2011
Clinical News

Ohr preclinical data

...of ocular toxicity or changes in intraocular pressure. In 2009, Ohr acquired Evizon squalamine from Genaera Corp....
...to reformulate the compound to develop it for the indication (see BioCentury, Dec. 7, 2009). Genaera's...
BioCentury | Mar 7, 2011
Clinical News

MEDI-528: Completed Phase IIb enrollment

...subcutaneous MEDI-528. Last May, Ligand acquired the milestone and royalty rights to MEDI-528 from Genaera Corp. Genaera...
...to develop mAbs against IL-9 (see BioCentury, May 31, 2010). Genaera's assets were transferred to Genaera...
Items per page:
1 - 10 of 326